off-the-shelf– tag –
-
Nkarta Develops Off-the-Shelf NK Cell Therapies NKX019 and NKX101 for Solid and Hematologic Malignancies, Balancing Scalability with Clinical Efficacy
Umbrex USA Overview Nkarta, a clinical-stage biotechnology company, specializes in off-the-shelf NK cell therapies derived from healthy donors, developing NKX019 for B-cell malignancies and NKX101 for Acute Myeloid Leukemia (AML) as its ... -
Engineered Allogeneic Treg Cell Therapy TRX103 Enters Phase 1/2a Clinical Trials for Crohn’s Disease and GvHD Prevention
Frontiers Global Overview The gene-edited allogeneic Treg cell therapy candidate TRX103, designed as a scalable, off-the-shelf application, has commenced Phase 1/2a clinical evaluation for Crohn's disease and Graft-versus-Host Disease (G... -
Cell Therapy Startups Like Orca Bio and Allogene Lead Cancer & Autoimmune Disease Treatment with Off-the-Shelf Platforms
New Market Pitch USA Overview Cell therapy startups such as Orca Bio and Allogene, utilizing off-the-shelf platforms, are spearheading advancements in allogeneic and iPSC-derived therapies for cancer and autoimmune diseases. Key differen... -
Nkarta Accelerates Clinical Development of Off-the-Shelf NK Cell Therapies NKX019 and NKX101 from Healthy Donors
Umbrex USA Overview Nkarta, a clinical-stage biotechnology company, focuses on off-the-shelf natural killer (NK) cell therapies, utilizing a platform that genetically engineers and cryopreserves healthy donor-derived NK cells. Its lead p... -
Frontiers Reports GMP-Compliant Scalable Manufacturing Platform Established for Allogeneic Type 1 Regulatory T Cells (TRX103)
Frontiers in Immunology Switzerland Overview A study published in Frontiers reports the establishment of a GMP-compliant, scalable manufacturing platform for TRX103, an allogeneic Type 1 regulatory T cell (Tr1 cell). While TRX103 has sho... -
Qihan Biotech’s Universal Dual-Target Hypoimmune CAR-T Therapy QT-019B Receives FDA RMAT and Breakthrough Therapy Designations
PackGene Biotech China Overview Qihan Biotech's universal dual-target CAR-T therapy, QT-019B, has received both FDA Regenerative Medicine Advanced Therapy (RMAT) and Breakthrough Therapy Designations (BTD). This off-the-shelf allogeneic ... -
FDA Grants RMAT Designation to Cellectis’ Allogeneic CD22 CAR-T Lasme-cel for Relapsed/Refractory B-ALL
Targeted Oncology USA Overview The FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation to Cellectis' lasmecabtagene timgedleucel (lasme-cel; UCART22), an allogeneic CD22-targeting CAR-T cell therapy, for relapsed/re... -
Century Therapeutics Unveils CNTY-813 iPSC-Derived Islet Replacement Preclinical Data at ADA 2026: Demonstrates Durable Glucose Control, Immune Evasion, and Scalable Manufacturing, IND Filing Expected Q4 2026
BioSpace (via GlobeNewswire) USA Overview Century Therapeutics presented new preclinical data for its iPSC-derived islet replacement therapy, CNTY-813, at the ADA 2026 Scientific Sessions. The data demonstrated durable glucose control, i... -
Preprint Reviews NKG2D CAR-NK Cell Progress in Cancer Immunotherapy: Low GVHD Risk, Scalable Manufacturing, and iPSC-Derived NK Cells as a Platform for Off-the-Shelf Therapies
Preprints.org International Overview A preprint on Preprints.org reviews recent progress in NKG2D CAR-NK cells for cancer immunotherapy, highlighting their favorable safety profile with rare instances of graft-versus-host disease (GVHD) ... -
CombiCult® Screening Platform Establishes Feeder-Free Bioreactor Scalability for iPSC-Derived NK Cell Manufacturing
Frontiers (Preprint) Germany Overview This preprint reports research developing a feeder-free protocol for generating mature, functional iPSC-derived natural killer (iNK) cells using the high-throughput combinatorial screening platform C...
